Early breast cancer

Brief Synopsis:

2020 has been marked by further advances in tailoring therapy for our patients facing breast cancer. We are refining the use of targeted HER-2 agents and selecting who can de-escalate therapy. More patients are being spared chemotherapy based on relevant biomarkers. Similarly, we have had large wins in predicting who will benefit from escalation above standard therapy to include immunotherapy in triple negative disease. In early breast cancer, finding the right size for the right patient is paramount not only to give patients’ the best possible outcome, but also ensure they are not exposed to unnecessary side effects from their therapy if lower risk.